NCT01843374 · OUTCOME

Number of Participants Reporting Any Serious Adverse Events

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participants
Interval / dispersion: Not reported
Time frame: Day 1 to 90 days post dose

Analysis population: Safety population

Groups in this outcome

PLACEBO

Placebo.

TREMELIMUMAB

Tremelimumab 10mg/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
PLACEBO	189
TREMELIMUMAB	380

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
PLACEBO	85	Not reported	Not reported	Not reported	Not reported
TREMELIMUMAB	218	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
85
group Id
OG001
value
218

denom Units Selected

Participants

denoms

counts
group Id
OG000
value
189
group Id
OG001
value
380
units
Participants

groups

description
Placebo.
id
OG000
title
PLACEBO
description
Tremelimumab 10mg/kg
id
OG001
title
TREMELIMUMAB

param Type

NUMBER

population Description

Safety population

reporting Status

POSTED

time Frame

Day 1 to 90 days post dose

title

Number of Participants Reporting Any Serious Adverse Events

type

SECONDARY

type Units Analyzed

Participants

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice